<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00981786</url>
  </required_header>
  <id_info>
    <org_study_id>A434</org_study_id>
    <nct_id>NCT00981786</nct_id>
  </id_info>
  <brief_title>24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol</brief_title>
  <official_title>Quality of 24-hour Intraocular Pressure Control Obtained With the Brinzolamide/Timolol Fixed Combination Compared With the Brimonidine/Timolol Fixed Combination When Added to Travoprost Monotherapy in Subjects With Open-angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed crossover study will compare for the first time the quality of 24-hour&#xD;
      intraocular pressure control with the combination of travoprost and brinzolamide/timolol&#xD;
      compared with travoprost and brimonidine/timolol in glaucoma patients insufficiently&#xD;
      controlled with travoprost. This comparison may determine the real efficacy of the two fixed&#xD;
      combinations when added to the prostaglandin. The design of the proposed study should&#xD;
      facilitate a better understanding of the role of these medications in glaucoma management.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean 24-hour intraocular pressure</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fluctuation of 24-hour intraocular pressure</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Brinzolamide/Timolol therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chronic therapy for 3 months with brinzolamide/timolol drops given twice daily added to travoprost drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brimonidine/Timolol therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chronic therapy for 3 months with brimonidine/timolol drops given twice daily added to travoprost drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine/timolol fixed combination drops added to travoprost</intervention_name>
    <description>twice daily administration</description>
    <arm_group_label>Brimonidine/Timolol therapy</arm_group_label>
    <arm_group_label>Brinzolamide/Timolol therapy</arm_group_label>
    <other_name>Combigan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brinzolamide/timolol fixed combination drops added to travoprost</intervention_name>
    <description>twice daily dosing</description>
    <arm_group_label>Brimonidine/Timolol therapy</arm_group_label>
    <arm_group_label>Brinzolamide/Timolol therapy</arm_group_label>
    <other_name>Azarga</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has open-angle glaucoma and is older than 29 years&#xD;
&#xD;
          -  Patients should exhibit typical disc, or field changes and an untreated morning IOP&#xD;
             greater than 25 mm Hg&#xD;
&#xD;
          -  Patients are treated for at least 3 months with travoprost and should have&#xD;
             demonstrated at least a 20% morning IOP reduction&#xD;
&#xD;
          -  Patient deemed by PI to require adjunctive therapy to obtain desired target IOP&#xD;
&#xD;
          -  Patient should exhibit IOP greater than 18 mm Hg on travoprost monotherapy (2 separate&#xD;
             IOP readings at 10:00)&#xD;
&#xD;
          -  Patient has mild to moderate glaucoma (field loss more than 16 dB; cupping 0.8 or&#xD;
             less)&#xD;
&#xD;
          -  Distance best corrected Snellen visual acuity at least 0.1&#xD;
&#xD;
          -  No contraindications to travoprost, brimonidine, brinzolamide and Î²-blockers&#xD;
&#xD;
          -  No history of lack of response (&lt;10% morning IOP reduction) to any medication&#xD;
&#xD;
          -  Patient can understand the instructions and adhere to medications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patient of childbearing potential or lactating mother&#xD;
&#xD;
          -  History of trauma, inflammation, surgery&#xD;
&#xD;
          -  History of past use of steroids (within 2 months), severe dry eyes and use of contact&#xD;
             lenses&#xD;
&#xD;
          -  Signs of ocular infection, except blepharitis&#xD;
&#xD;
          -  Evidence of corneal abnormality that may affect IOP measurements etc&#xD;
&#xD;
          -  Closed angle&#xD;
&#xD;
          -  History of non-compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>29 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anastasios G Konstas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glaucoma Unit, 1st University Department of Ophthalmology</affiliation>
  </overall_official>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 16, 2009</study_first_submitted>
  <study_first_submitted_qc>September 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>AGP Konstas</investigator_full_name>
    <investigator_title>Professor in Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>24-hour IOP control</keyword>
  <keyword>brinzolamide/timolol</keyword>
  <keyword>brimonidine/timolol</keyword>
  <keyword>travoprost</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Travoprost</mesh_term>
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

